Does intestinal ultrasound combined with visceral adipose tissue more accurately predict primary non-response to infliximab in patients with Crohn's disease? A prospective, observational study.
Background: Infliximab (IFX) is widely used for the treatment of Crohn’s disease (CD), yet up to 40% patients experience primary non-response (PNR). Visceral adipose tissue (VAT) and intestinal ultrasound (IUS) could be used as noninvasive tools to predict treatment efficacy with limited value, respectively. Objectives: This study aims to investigate the value of IUS combined with VAT in predicting PNR in CD patients. Design: This was a single-center, prospective, and observational study....